What is the likely cause and recommended management for three months of breakthrough bleeding after a Depo‑Provera (medroxyprogesterone acetate) injection?

Management of Breakthrough Bleeding After Depo-Provera

Breakthrough bleeding for three months after Depo-Provera is an expected side effect that occurs in the majority of new users during the first 6 months, and the recommended first-line management is reassurance combined with NSAIDs for 5–7 days during bleeding episodes. 1

Understanding the Cause

• Irregular bleeding patterns, including breakthrough bleeding, spotting, and prolonged bleeding, are the most common side effects of depot medroxyprogesterone acetate (DMPA) and occur in up to 70% of users during the first year. 2, 3
• This bleeding results from progestin-induced endometrial changes that create an atrophic, fragile endometrium prone to irregular shedding. 2
• Bleeding irregularities typically improve over time, with 30–40% of adolescent users achieving amenorrhea by 3–6 months of continued use. 4
• The FDA label explicitly states that DMPA is not recommended for dysfunctional uterine bleeding because of its prolonged action and unpredictable withdrawal bleeding patterns. 5

Initial Assessment

Before treating breakthrough bleeding as a benign DMPA side effect, you must exclude other causes:

• Rule out pregnancy with a serum β-hCG test, even in contraceptive users, as unintended pregnancy can occur and has been reported as a significant adverse event in DMPA users. 6, 7
• Perform a speculum examination to exclude cervical or vaginal sources of bleeding, including sexually transmitted infections, cervical pathology, or trauma. 1, 6
• The FDA label emphasizes that in cases of undiagnosed, persistent, or recurrent abnormal vaginal bleeding, appropriate measures should be conducted to rule out malignancy. 5
• Consider thyroid dysfunction, coagulopathy, or new uterine pathology (polyps, fibroids) if bleeding is unusually heavy or the patient has risk factors. 6

First-Line Management Strategy

If no pathologic cause is identified and the patient wishes to continue DMPA, provide reassurance and offer NSAIDs as symptomatic treatment:

• NSAIDs for 5–7 days during bleeding episodes are the recommended first-line pharmacologic intervention for DMPA users with breakthrough bleeding. 1
• NSAIDs reduce menstrual blood loss by inhibiting prostaglandin synthesis in the endometrium. 2
• Counsel the patient that bleeding irregularities are expected during the first 3–6 months and typically improve with continued use. 2, 4
• Advise the patient to contact you at any time to discuss side effects or if they wish to discontinue the method. 1

Alternative and Adjunctive Options

If NSAIDs alone are insufficient or contraindicated:

• Supplemental estrogen (e.g., low-dose combined oral contraceptives or estrogen alone) for 10–20 days can be added to stabilize the endometrium and reduce bleeding. 1, 2
• One older study found that prior use of oral contraceptives before starting DMPA significantly reduced bleeding duration during the first 6 months (5.7 days vs. 17.1 days), though this effect did not persist beyond 6 months. 8
• Avoid early second injection (at 6 weeks instead of 12 weeks), as this strategy does not reduce bleeding and is associated with excessive weight gain. 8

When Standard Management Fails

If bleeding persists beyond 3 months despite NSAIDs and reassurance, or if the patient cannot tolerate the bleeding:

• Offer method discontinuation and counsel on alternative contraceptive options, including long-acting reversible contraceptives (LARCs) such as the levonorgestrel IUD or etonogestrel implant, which have lower rates of irregular bleeding over time. 1, 9
• If the patient prefers to continue DMPA, consider a trial of supplemental estrogen for 10–20 days. 1
• Experimental data suggest that mifepristone 50 mg every 2 weeks significantly reduces breakthrough bleeding in DMPA users, though this is not standard practice and is not FDA-approved for this indication. 10

Critical Caveats

• Do not prescribe NSAIDs to patients with cardiovascular disease, history of myocardial infarction, or spontaneous coronary artery dissection, as NSAIDs increase thrombotic risk. 6
• Do not use tranexamic acid in DMPA users with breakthrough bleeding, as it is not listed as a recommended treatment for injectable contraceptive users in the CDC guidelines and carries thrombotic risk. 1
• Do not perform routine pelvic examination before initiating or continuing DMPA unless clinically indicated by symptoms or findings. 9
• Be aware that prolonged DMPA use (>4 years) or initiation after age 31 has been associated with increased risk of meningioma, though the absolute risk remains low (number needed to harm = 1152). 11

Shared Decision-Making

• Explore the patient's goals: Does she want to continue DMPA with treatment for bleeding, or does she prefer to switch methods? 1
• Emphasize that amenorrhea, which many patients find desirable, is likely to develop with continued use. 4
• If the patient chooses to discontinue DMPA, offer immediate initiation of an alternative method to prevent unintended pregnancy. 1, 9